About this trial
Biliary atresia is the most severe form of cholestatic liver disease. The children have high morbidity and mortality and get devastating pruritus and fatigue, failure to thrive, progressive hepatic failure and impaired neurodevelopment. The etiology is mostly unknown. More than half need a new liver from a living or deceased donor during childhood. However, correct timing of the transplantation is extremely difficult because of lack of consensus based on clinical assessment tools. All though the incidence is low, the cost of this disease is tremendous from both a clinical and human perspective. So far, protocolized neurodevelopment tests, genetic profiling, precise malnutrition evaluation based on clinical appearance, biochemical markers and brain MRI-scans, body composition, immunological function, level of physical activity and optimal time of transplantation in cholestatic children are unknown.
The aim is to determine risk factors for neurocognitive impairment in children suffering from severe cholestasis in order to determine optimal time for liver transplantation from a brain perspective.
In a prospective study, the investigators will investigate risk factors related to brain-, heart-, gut- and immunological function in the Danish cohort. This cohort consists of 75 children aged 0-18 years. In addition, 30 aged and gender matched healthy and 20 tetra fallot children will serve as control groups. The children will undergo extensive and advanced liver function evaluation, genetic profiling, nutrition and immunological status, neuro-imaging and neurocognitive evaluation at time of diagnose, 2 years of age, pre-school, pre-teenage, and teenage. In case of a liver transplantation, additional neuro-cognitive tests will be performed
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Biliary atresia
Tetralogy of Fallot
Healthy controls
Disqualifiers
None
Trial population
Children with biliary atresia (BA), children with Tetralogy of Fallot (ToF) and healthy control children between the age of 0-17 years. The BA and ToF children were recruited from their respective outpatient clinics at Rigshospitalet, Denmark, which is the only centre treating these patients. Healthy controls were siblings to BA children, recruited from staffs children and friends or recruited from a general practitioners office in Nivaa, Denmark. The recruitment took place from March 2020 and is ongoing
Trial design
Case-control
Prospective
Treatments tested in this trial
Neurocognitive monitoring
Other interventionNeurocognitive tests and MRI of the brain
Treatment groups
Trial outcomes
Primary outcomes
MRI of the brain
% of patients with anatomic anomalies on MRI of the brain
Neurocognitive status: Early movement repertoire (General movement)
Neurocognitive test panel depending on age at inclusion % of patients with of abnormal movement assessed using early movement repertoire (GM) if inclusion at diagnosis. Early movement repertoire is a measurement tool where abnormal movement is identified.
Neurocognitive status: Alberta Infant Motor Scale
Neurocognitive test panel depending on age at inclusion: Alberta Infant Motor Scale if inclusion at diagnosis Percentile, highest is the best
Neurocognitive status: Bayley Scales of Development III
Neurocognitive test panel depending on age at inclusion: Bayley Scales of Development III if inclusion up to 2.5 years: From 0-200, highest is best
Secondary outcomes
Genetics: Whole genome sequencing of blood
Whole genome sequencing of blood
Genetics: Whole genome sequencing of liver biopsy
Whole genome sequencing of liver biopsy
Microbiome: Urine proteomics
Microbiome measurements on urine
Microbiome: Feces proteomics
Microbiome measurements on feces
Sponsors and contacts
Click on the lead sponsor to view all of their trials.